RORing T cells target CLL and MCL Journal Article


Author: Sadelain, M.
Article Title: RORing T cells target CLL and MCL
Abstract: Genetically targeted T lymphocytes are emerging as powerful antitumor agents. Their rapid generation, made possible by robust and clinically applicable gene transfer technologies, provides a novel means to circumvent immune tolerance and generate tumor-reactive T cells on demand. Thus, patient peripheral blood T cells can be readily redirected toward any chosen antigen, including tumor antigens which are for the most part "self" antigens, and infused to promptly raise the number of tumor-reactive T cells without requiring active immunization and without the risk of deleterious alloreactivity (as may be the case after donor leukocyte infusion or non-T cell-depleted bone marrow transplantation).
Keywords: unclassified drug; note; protein domain; t lymphocyte; cell survival; gene targeting; mantle cell lymphoma; cell differentiation; antineoplastic activity; cytotoxicity; acute lymphoblastic leukemia; b lymphocyte; gene transfer; t lymphocyte receptor; immunological tolerance; nonhodgkin lymphoma; carbonate dehydratase ix; genetic engineering; antigen specificity; cancer cell; antigen recognition; retrovirus vector; hematopoietic cell; chimeric antigen receptor; donor lymphocyte infusion; target cell; melan a; bone marrow transplantation; chronic lymphatic leukemia; wnt protein; hla antigen; cd19 antigen; lymphocyte antigen receptor; lymphocyte function; fetus development; peripheral lymphocyte; frizzled protein; alloimmunity; ror1 protein; active immunization; kringle domain
Journal Title: Blood
Volume: 116
Issue: 22
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2010-11-25
Start Page: 4387
End Page: 4388
Language: English
DOI: 10.1182/blood-2010-09-303388
PROVIDER: scopus
PUBMED: 21109622
DOI/URL:
Notes: --- - "Export Date: 20 April 2011" - "CODEN: BLOOA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Michel W J Sadelain
    583 Sadelain